On your marks, get SET(D1A)::the race to protect stalled replication forks by Begum, Shabana et al.
 
 
University of Birmingham
On your marks, get SET(D1A):
Begum, Shabana; Goula, Amalia; Bayley, Rachel; Higgs, Martin
DOI:
10.1080/23723556.2018.1511209
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Begum, S, Goula, A, Bayley, R & Higgs, M 2018, 'On your marks, get SET(D1A): the race to protect stalled
replication forks', Molecular and Cellular Oncology, vol. 5, no. 6, e1511209.
https://doi.org/10.1080/23723556.2018.1511209
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=kmco20
Molecular & Cellular Oncology
ISSN: (Print) 2372-3556 (Online) Journal homepage: http://www.tandfonline.com/loi/kmco20
On your marks, get SET(D1A): the race to protect
stalled replication forks
Shabana Begum, Amalia Goula, Rachel Bayley & Martin R. Higgs
To cite this article: Shabana Begum, Amalia Goula, Rachel Bayley & Martin R. Higgs (2018):
On your marks, get SET(D1A): the race to protect stalled replication forks, Molecular & Cellular
Oncology, DOI: 10.1080/23723556.2018.1511209
To link to this article:  https://doi.org/10.1080/23723556.2018.1511209
© 2018 The Author(s). Published by Taylor &
Francis Group, LLC
Published online: 11 Oct 2018.
Submit your article to this journal 
Article views: 14
View Crossmark data
AUTHOR'S VIEWS
On your marks, get SET(D1A): the race to protect stalled replication forks
Shabana Begum, Amalia Goula , Rachel Bayley, and Martin R. Higgs
Lysine Methylation and DNA Damage Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
ABSTRACT
We recently identified that methylation of lysine 4 of histone H3 (H3K4) by SETD1A (SET domain
containing 1A) maintains genome stability by protecting newly-replicated DNA from degradation.
Mechanistically, SETD1A-dependent histone methylation regulates nucleosome mobilisation by
FANCD2 (FA complementation group D2), a crucial step in maintaining genome integrity with important
implications in chemo-sensitivity.
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Duplication of the cellular genome by DNA replication is a
highly regulated process crucial for cellular and organismal
homeostasis. Compromising this regulation leads to slowing
or stalling of replication forks, known as replication stress,
which if unresolved gives rise to genome instability.1
Signatures of replication stress-associated genetic damage are
observed in pre-cancerous as well as tumoural cells.
Therefore, since loss of genomic integrity is a well-recognised
hallmark of cancer, DNA replication stress is likely a key
driver of cancer development.
Given this, it is unsurprising that numerous factors have
developed to counteract the negative consequences of unre-
solved replication stress, preserving genome stability and
maintaining human health. One key event mediated by these
proteins is the active reversal of paused/stalled replication
forks;2 the formation of these reversed forks is vital in pro-
tecting genome integrity. Moreover, they must also be pro-
tected from uncontrolled degradation by cellular nucleases
(reviewed in ref)3: if forks are unprotected and subsequently
degraded, this also leads to severe genome instability.
Reversed forks are protected through the actions of a number
of factors including the tumour suppressor genes BRCA1
(BRCA1, DNA repair associated) and BRCA2 (BRCA2,
DNA repair associated), as well as other components of the
homologous recombination and Fanconi anaemia (FA) repair
pathways. Crucially, loss of fork protection has potential clin-
ical implications during cancer therapy, since the ability of
tumour cells to acquire drug resistance is intimately linked to
their ability to protect replication forks from degradation,4
(Figure 1A-B). However, despite the clinical importance of
fork protection, we do not fully understand how reversed
forks are marked to elicit protection, and in particular how
post-translational chromatin modifications may play a role. A
recent publication from our group in Molecular Cell has shed
further light on the mechanisms by which cells label stalled
replication forks for protection.5 We identified that protection
of replication forks under conditions of replication stress
requires SETD1A (SET domain containing 1A), a member
of the KMT2 family of lysine methyltransferases, well known
for their ability to catalyse methylation of lysine 4 of histone
H3 (H3K4). We showed that SETD1A depletion exposes
reversed replication forks to nucleolytic degradation upon
replication stress, increasing genome instability and hyper-
sensitising cells to agents that induce replication stress.
Moreover, although both SETD1A and SETD1B (SET domain
containing 1B, a closely related member of the KMT2 family)
methylate H3K4, only the catalytic activity of SETD1A is
required for fork protection. Mechanistically, by methylating
H3K4 at/near reversed replication forks, SETD1A prevents
the RAD51 recombinase from being destabilised away from
these sites, safeguarding nascent DNA from uncontrolled
resection by the helicase/nuclease DNA2.
Importantly, this SETD1A-dependent protection is mediated
by controlling access/activity of chromatin remodelling factors:
firstly, SETD1A-dependent H3K4methylation limits fork degra-
dation by preventing access of Chromodomain helicase DNA
binding protein 4 (CHD4; a nucleosome remodelling factor and
component of the NuRD complex) to reversed forks (Figure 1C).
Although it is unclear how CHD4 promotes fork degradation,
we hypothesise that it may promote chromatin ‘shuffling’ and
therefore allow access of nucleases to newly synthesized DNA.
Secondly, we showed that SETD1A and H3K4 methylation
functions together with the DNA-damage dependent histone
chaperone FANCD26 (FA complementation group D2) to
enhance histone mobility at stalled forks, further protecting
these structures from degradation by helping to stabilise the
RAD51 recombinase. Thus, our findings suggest that epigenetic
histone modifications catalysed by SETD1A are required to
tightly control the access and/or function of histone remodelling
factors at stalled replication forks, preventing nucleolytic degra-
dation of nascent DNA.
It is clear from a number of studies, including ours, that
the KMT2 family of H3K4 KMTs play crucial roles in con-
trolling the recruitment and/or activity of factors that regulate
CONTACT Martin R. Higgs m.r.higgs@bham.ac.uk
Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/kmco.
MOLECULAR & CELLULAR ONCOLOGY
https://doi.org/10.1080/23723556.2018.1511209
© 2018 The Author(s). Published by Taylor & Francis Group, LLC
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
A.
SENSITIVITY
B.
KMT2C/D
CHD4
Me
Me
BRCA1/2
Chemotherapeutic
response
RESISTANCE
KMT2C/D
BRCA1/2
CHD4
SENSITIVITY
Me
Me?
?
RESISTANCE
CHD4
SETD1A
RESISTANCE
CHD4
SETD1A
SETD1A
Me
Me
CHD4
Fork
degradation
Fork
stability
Fork
degradation
Fork
stability
Fork
stability
BRCA1/2
C.
D.
E.
Figure 1. Histone methylation, fork protection and chemo-resistance. A) In the absence of BRCA1/BRCA2 tumour suppressors (dotted oval), fork degradation is
driven by the helicase CHD4 and by KMT2C/KMT2D4. This fork degradation gives rise to the chemotherapeutic sensitivity of tumoural cells. Histone methylation on
lysine 4 of histone H3 (H3K4 Me; yellow pentagons) by KMT2C/KMT2D seems to have no effect on CHD4 activity in this context. B) Loss of CHD4 in BRCA-deficient
cells restores fork stability, giving rise to resistance to chemotheurapeutic agents such as mitomycin C. C) In contrast, our paper5 demonstrates that SETD1A-mediated
histone methylation protects forks, even in the absence of BRCA1/BRCA2. This would render tumoural cells less sensitive to replication-stress inducing agents. D)
Upon loss of SETD1A (dotted teardrop), loss of H3K4 methylation allows CHD4 to drive fork degradation, leading to fork instability and chemo-sensitivity. E) As in
BRCA -deficient cells, loss of CHD4 restores fork stability but leads to chemotherapeutic resistance. Thus, restoration of fork protection through disparate mechanisms
in different genetic contexts accounts for the development of chemo-resistance in tumoural cells.
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fork stability. Interestingly, other KMTs (such as EZH27
(Enhancer of zeste 2 polycomb repressive complex 2 subunit))
also play a role in fork protection, further underlining the
importance of epigenetic modifications in this process.
However, perhaps counter-intuitively, different KMT2
enzymes elicit different responses within similar genetic back-
grounds, despite the fact that they all target H3K4 for methy-
lation. This is illustrated by studies demonstrating that, in
contrast to our findings, KMT2C & KMT2D (Lysine methyl-
transferase 2C & D; also known as MLL3 and MLL2 respec-
tively) actually promote nascent strand degradation in the
presence of impaired fork protection (e.g. BRCA2-deficient
tumour cells)4. In contrast, it is clear from our findings5 that
SETD1A functions constitutively to protect forks, regardless
of whether or not fork stability has already been compro-
mised, and that it regulates fork stability via numerous
mechanisms. This discrepancy is in agreement with murine
studies suggesting that there is little functional redundancy
between the six KMT2 family members. Therefore, identifying
how each KMT functions in different genetic backgrounds to
protect forks is fundamental to further understanding
acquired chemoresistance.
Despite the differing roles of BRCA1, BRCA2 and SETD1A
in mediating fork protection, and the contrasts between
SETD1A, SETD1B, KMT2C and KMT2D, it is also clear that
different fork ‘protection factors’ can also prevent DNA
degradation via common mechanisms. Indeed, both BRCA1/
BRCA2 and SETD1A suppress CHD4-mediated fork
degradation4,5 (Figure 1). Moreover, our findings have impor-
tant clinical consequences, since loss of CHD4 in primary and
BRCA-deficient tumour cells confers resistance to treatment
with poly ADP ribose polymerase (PARP) inhibitors and
cisplatin.8 Thus, CHD4 represents a common mechanism
that drives fork degradation in the absence of protective
factors, perhaps by promoting fork reversal or by regulating
local chromatin environments, and this in turn leads to
chemo-sensitivity. Loss of CHD4 in these genetic back-
grounds would therefore engender chemo-resistance in what
would otherwise be sensitive tumour cells (Figure 1B and E).
Therefore, identifying how the cell protects nascent DNA is a
crucial step towards defining the mechanisms by which
tumour cells acquire resistance to commonly used chemother-
apeutic agents.
Much more work clearly remains in elucidating how dif-
ferent members of the same KMT family elicit such markedly
different effects within diverse genetic backgrounds.
Moreover, future studies on the regulation of lysine methyla-
tion, and the identification of other KMTs that play a role in
this process, would contribute substantially towards our
understanding of fork stability. This in turn could open new
and exciting avenues towards the development of more effi-
cient chemotherapeutic agents or strategies.
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